Nevro Corp. (NVRO)
5.73
0.01 (0.17%)
At close: Mar 03, 2025, 3:59 PM
5.72
-0.17%
After-hours: Mar 03, 2025, 04:10 PM EST
Nevro Corp. Revenue Breakdown
| Quarter | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Painful Diabetic Neuropathy Revenue | 22.5M | 20.8M | 19M | 15.6M | 17.6M | 13.4M | 11M | 6M | 1.7M |
| Painful Diabetic Neuropathy Revenue Growth | +8.17% | +9.47% | +21.79% | -11.36% | +31.34% | +21.82% | +83.33% | +252.94% | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Non-Us Revenue | 58.62M | 58.2M | 326.22M | 311.87M | 326.01M | 321.78M |
| Non-Us Revenue Growth | +0.72% | -82.16% | +4.60% | -4.34% | +1.31% | n/a |
| United States Revenue | 366.56M | 348.17M | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +5.28% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 68.47M | 76.77M | 85.09M | 77.82M | 81.15M | 86.76M | 86.19M | 80.65M | 78.19M | 83.97M | 79.33M | 82.64M | 79.52M | 73.88M | 73.27M | 67.07M | 68.51M | 60.17M | 71.4M | 76.01M | 72.91M | 75.57M | 81.33M | 71.28M | 64.01M | 64.71M | 66.62M | 61.74M | 52.98M | 54.27M | 50.72M | 43.83M | 35.64M | 34.31M | 28.64M | 27.62M | 21.9M | 19.82M | 13.13M |
| Selling, General, and Administrative Revenue Growth | -10.81% | -9.78% | +9.35% | -4.11% | -6.47% | +0.66% | +6.87% | +3.15% | -6.89% | +5.86% | -4.01% | +3.92% | +7.64% | +0.83% | +9.24% | -2.10% | +13.87% | -15.73% | -6.06% | +4.25% | -3.53% | -7.08% | +14.10% | +11.36% | -1.08% | -2.87% | +7.90% | +16.54% | -2.39% | +7.01% | +15.71% | +23.00% | +3.86% | +19.79% | +3.69% | +26.16% | +10.46% | +50.97% | n/a |
| Research and Development Revenue | 10.58M | 14.12M | 14.83M | 12.42M | 13.92M | 13.32M | 14.76M | 13.95M | 14.03M | 12.55M | 12.54M | 12.71M | 11.55M | 11.87M | 11.53M | 11.83M | 11.11M | 10.44M | 12.21M | 16.93M | 13.02M | 14.93M | 14.13M | 13.48M | 12.48M | 11.42M | 11.09M | 9.94M | 9.38M | 9.54M | 8.7M | 11.28M | 7.92M | 8.17M | 6.36M | 5.87M | 5.25M | 5.26M | 5M |
| Research and Development Revenue Growth | -25.06% | -4.79% | +19.39% | -10.80% | +4.53% | -9.73% | +5.79% | -0.59% | +11.78% | +0.13% | -1.36% | +10.01% | -2.66% | +2.90% | -2.50% | +6.44% | +6.42% | -14.48% | -27.88% | +30.06% | -12.80% | +5.62% | +4.86% | +8.03% | +9.30% | +2.99% | +11.49% | +5.99% | -1.64% | +9.63% | -22.85% | +42.32% | -3.01% | +28.42% | +8.29% | +11.95% | -0.30% | +5.30% | n/a |